MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


0026-895X/04/6501-149-156$20.00
Mol Pharmacol 65:149-156, 2004

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Al-Ani, B.
Right arrow Articles by Hollenberg, M. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Al-Ani, B.
Right arrow Articles by Hollenberg, M. D.

Proteinase-Activated Receptor-2: Key Role of Amino-Terminal Dipeptide Residues of the Tethered Ligand for Receptor Activation

Bahjat Al-Ani1, Kristina K. Hansen, and Morley D. Hollenberg

Diabetes/Endocrine (B.A.-A., K.K.H., M.D.H.) and Mucosal Inflammation (K.K.H., M.D.H.) Research Groups, Departments of Pharmacology and Therapeutics (B.A.-A., K.K.H., M.D.H.) and Medicine (K.K.H., M.D.H.), the University of Calgary Faculty of Medicine, Calgary, Alberta, Canada

Tryptic cleavage of proteinase-activated receptor-2 (PAR2) causes the unmasking of a tethered receptor-activating sequence, S37LIGRLDTP.... We sought to determine, in the amino-terminal sequence of the PAR2 tethered ligand, the key amino acid residues that are responsible for receptor activation. Using site-directed mutagenesis, nine PAR2 mutants with alanine substitutions in the first six amino acids of the tethered ligand, S37LIGRL42..., were prepared: PAR2S37A, PAR2L38A, PAR2I39A, PAR2G40A, PAR2R41A, PAR2A37-38, PAR2A39-42, PAR2A37,39-42, and PAR2A37-42, along with the reverse-sequence construct, PAR2L37S38. These mutants, together with wild-type PAR2(PAR2wt), were expressed in Kirsten virus-transformed rat kidney cells and were then assessed for receptor-mediated calcium signaling upon activation by trypsin and by receptor-activating peptides like SLIGRL-NH2. In addition, the release of the N-terminal receptor sequence that is cleaved from PAR2 by trypsin activation was monitored in the above cell lines using a site-targeted anti-receptor antibody. All PAR2 constructs were activated by SL-NH2, and all mutated tethered ligand sequences were unmasked by trypsin. However, differential activation of the receptor by trypsin in these mutants was observed: PAR2 mutants PAR2A37-38 and PAR2L37S38, in which the first two amino-terminal tethered ligand residues (S37L38) are either changed to alanines or reversed, yielded little or no response to trypsin, nor did PAR2A37,39-42. However, trypsin activated all other constructs. We conclude that the amino-terminal tethered ligand dipeptide sequence S37L38 plays a major role in the activation of PAR2.


Received June 27, 2003; accepted September 29, 2003

Address correspondence to: Morley D. Hollenberg, Department of Pharmacology and Therapeutics, University of Calgary Faculty of Medicine, 3330 Hospital Dr. N.W., Calgary, AB Canada T2N 4N1. E-mail: mhollenb{at}ucalgary.ca




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
M. D. Hollenberg, B. Renaux, E. Hyun, S. Houle, N. Vergnolle, M. Saifeddine, and R. Ramachandran
Derivatized 2-Furoyl-LIGRLO-amide, a Versatile and Selective Probe for Proteinase-Activated Receptor 2: Binding and Visualization
J. Pharmacol. Exp. Ther., August 1, 2008; 326(2): 453 - 462.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
K. Hirano, N. Nomoto, M. Hirano, F. Momota, A. Hanada, and H. Kanaide
Distinct Ca2+ Requirement for NO Production between Proteinase-Activated Receptor 1 and 4 (PAR1 and PAR4) in Vascular Endothelial Cells
J. Pharmacol. Exp. Ther., August 1, 2007; 322(2): 668 - 677.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Cell Mol. Bio.Home page
R. Ramachandran, A. H. Morice, and S. J. Compton
Proteinase-Activated Receptor2 Agonists Upregulate Granulocyte Colony-Stimulating Factor, IL-8, and VCAM-1 Expression in Human Bronchial Fibroblasts
Am. J. Respir. Cell Mol. Biol., July 1, 2006; 35(1): 133 - 141.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. Swift, A. J. Leger, J. Talavera, L. Zhang, A. Bohm, and A. Kuliopulos
Role of the PAR1 Receptor 8th Helix in Signaling: THE 7-8-1 RECEPTOR ACTIVATION MECHANISM
J. Biol. Chem., February 17, 2006; 281(7): 4109 - 4116.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. N. McLaughlin, L. Shen, M. Holinstat, J. D. Brooks, E. DiBenedetto, and H. E. Hamm
Functional Selectivity of G Protein Signaling by Agonist Peptides and Thrombin for the Protease-activated Receptor-1
J. Biol. Chem., July 1, 2005; 280(26): 25048 - 25059.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics